Labcorp Holdings Inc.
LH Healthcare Diagnostics & Research
Labcorp Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.0 billion, up 7.25% from fiscal 2024.
- Revenue
- +6.92%
- EPS
- +3.18%
- Free cash flow
- +44.7%
- Total debt
- +3.21%
Quarter to September 2026, against a year earlier
Follow LH
Alert me
Labcorp Holdings Inc. 10-Q filed Oct 31, 2025
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 1, 2025: 5 added · 2 removed · 35 modified; 14 with only figures updated
-
Modified · FORWARD-LOOKING STATEMENTS
In this Quarterly Report on Form 10-Q (Quarterly Report), Labcorp® Holdings Inc. together with its subsidiaries (Labcorp, LHI or the Company) has made, and from time to time may otherwise make in its public filings, press releases, and discussions by Company management, forward-looking statements concerning the Company’s operations, performance, and financial condition, as well as its strategic objectives. Some of these forward-looking statements relate to future events and expectations and can be identified by the use of forward-looking words such as “believes”, “expects”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates”, or “anticipates” or the negative of those words or other comparable terminology. Such forward-looking statements speak only as of the time they are made and are subject to various risks and uncertainties and the Company claims the protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those currently anticipated due to a number of factors in addition to those discussed elsewhere herein, including in the “Risk Factors” section of the Annual Report on Form 10-K, and in the Company’s other public filings, press releases, and discussions with Company management, including: